Erdafitinib for FGFR-mutated urothelial carcinoma

Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the first results of the primary analysis of the Phase II BLC2001 study (NCT02365597) of erdafitinib in patients with metastatic or unresectable urothelial carcinoma with FGFR alterations. Notably, immune ‘cold’ patients were observed to respond well to erdafitinib. Dr Siefker-Radtke highlights interesting future directions for this research. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.